AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00512018 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NMES
Description: In the contralateral limb, the same protocol was repeated; however, each contraction was associated with overlapped NMES (Ex+NMES limbs).For the NMES, a symmetric double-phase sine-wave was used. Bearing wave frequency was of 2500 Hz, modulated in 50 bursts/s, with pulse duration of 200 µs, interburst interval of 10 ms. This configuration is known as Russian current.
Study NCT00512018 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Isokinetic exercise
Description: Subjects realized training sessions twice a week with a 2-day minimum interval between the sessions, for 4 weeks. Each session included 5 min period of warm-up in a stationary bicycle, followed by 3 series of quadriceps stretching, as previously described. After being positioned at the isokinetic dynamometer, just as in the evaluation sessions, subjects firstly performed 3 sets of 10 maximum isokinetic concentric repetitions at the speed of 30º/s with one limb (EX limb), respecting the rest interval of 3 minutes between the sets.
Study NCT01509469 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Casein
Description: Ileal infusion of low dose casein (5 gram)
Study NCT01509469 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Casein
Description: Ileal infusion of high dose casein (15 gram)
Study NCT01509469 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sucrose
Description: Ileal infusion of low dose sucrose (4.3 gram)
Study NCT01509469 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sucrose
Description: Ileal infusion of high dose sucrose (12.9 gram)
Study NCT01509469 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Ileal infusion with saline (180mL in total)
Study NCT01509469 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Safflower oil
Description: Ileal infusion with safflower oil (6gr safflower oil in water)
Study NCT04566653 — intervention group
Intervention type: DRUG
Intervention: Calcium Polystyrene Sulphonate 15g/60 mL water
Description: K+ binder, not for treatment but for tasting (sip-and-spit taste test)
Study NCT04566653 — intervention group
Intervention type: DRUG
Intervention: Lokelma® 5 g/45mL water
Description: K+ binder, not for treatment but for tasting (sip-and-spit taste test)
Study NCT04566653 — intervention group
Intervention type: DRUG
Intervention: Lokelma® 10 g/45 mL water
Description: K+ binder, not for treatment but for tasting (sip-and-spit taste test)
Study NCT04566653 — intervention group
Intervention type: DRUG
Intervention: Veltassa® 8,4 g/80mL water
Description: K+ binder, not for treatment but for tasting (sip-and-spit taste test)
Study NCT04566653 — intervention group
Intervention type: DRUG
Intervention: Sodium Polystyrene Sulphonate 15g/60 mL water
Description: K+ binder, not for treatment but for tasting (sip-and-spit taste test)
Study NCT01236872 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beetroot juice
Description: 250ml once of beetroot juice
Study NCT01236872 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: 250ml once of low-nitrate mineral water
Study NCT03957941 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FamilyLink Pumping
Description: Viewing baby via FamilyLink while pumping
Study NCT03957941 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Pumping
Description: Not viewing baby via FamilyLink while pumping
Study NCT04528615 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CCK In-Person Sessions
Description: This group attended eight weeks of nutrition education-focused experiential learning.
Study NCT04528615 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CCK Printed Materials
Description: This group did not attend any in-person sessions and was only provided with select CCK written materials.
Study NCT01789983 — intervention group
Intervention type: BEHAVIORAL
Intervention: Walk With Ease Program
Description: The primary activity required of study subjects is a 6-week self-directed (non-group) WWE walking program that study participants do at a place and time that is convenient for them. To start the intervention/program, we schedule a brief baseline meeting with study participants to discuss the program, provide the WWE workbook, secure printed informed consent, and complete various questionnaires. Study participants are also asked to maintain a daily walking diary that is provided to them.~The WWE program includes a workbook with strengthening and stretching exercises, basic facts about arthritis and PA, and information on how to individualize the program.
Study NCT01789983 — intervention group
Intervention type: OTHER
Intervention: Collect Blood, GA and Other Survey Tools
Description: * Geriatric Assessment (GA) (Version 5)~* Functional Assessment of Cancer Therapy-General (FACT)~* Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue36~* Outcome Expectations for Exercise (OEE) scale29~* Self-Efficacy to Manage Arthritis or Joint Pain (ASE/Arthritis Self-Efficacy)~* Perceived Self-Efficacy for Fatigue Self-Management (PSEFSM)34,35~* Visual Analog Scales (VAS)~Surveys included in study are listed above. Whole Blood Sample will be collected for p16 analysis.
Study NCT02061397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Eligible patients on sirolimus or everolimus will be assigned to receive 20 mg of simvastatin once daily for a period of two months. If tolerated, the dosage of simvastatin will be advanced to 40 mg once daily in months 3 and 4.
Study NCT02061397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus Oral Product
Description: Eligible patients on sirolimus will be assigned to receive 20 mg of simvastatin once daily for a period of two months. If tolerated, the dosage of simvastatin will be advanced to 40 mg once daily in months 3 and 4.
Study NCT01542632 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Takeda's Tetravalent Dengue Vaccine Candidate (TDV)
Description: TDV subcutaneous injection
Study NCT01542632 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TDV New Formulation
Description: TDV New Formulation subcutaneous injection
Study NCT01542632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo subcutaneous injection
Study NCT01542632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: New Formulation Placebo
Description: New Formulation placebo subcutaneous injection
Study NCT03903861 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose alone
Description: Young men or women will complete a glycogen depleting bout of exercise followed by the provision of glucose-alone over 4 hours of recovery before a subsequent bout of exercise.
Study NCT03903861 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Galactose alone
Description: Young men or women will complete a glycogen depleting bout of exercise followed by the provision of galactose-alone over 4 hours of recovery before a subsequent bout of exercise.
Study NCT03903861 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose and galactose
Description: Young men or women will complete a glycogen depleting bout of exercise followed by the provision of glucose and galactose over 4 hours of recovery before a subsequent bout of exercise.
Study NCT01635387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aliskiren
Description: 150 mg once a day per 2 week with forced uptitration to 300 mg once a day, if tolerated
Study NCT01635387 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: aliskiren
Description: 150 mg once a day per 2 week with forced uptitration to 300 mg once a day, if tolerated
Study NCT04759040 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Migraineguard
Description: 2 Capsules per day for 7 Months
Study NCT04759040 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Migraineguard
Description: 2 Capsules per day for 7 Months
Study NCT00099606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Tablets, Oral, Dose Finding Study - Range was 35 mg BID, 5 days on/2 days off - 120 mg BID Continuous Daily Dosing, Once daily, Patients remained on study until treatment discontinuation due to unacceptable toxicity, disease progression or death.
Study NCT02913885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curodont Repair
Description: composed of biomimetic regeneration scaffold self-assembling peptides (P11-4) used for remineralization
Study NCT02913885 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Curodont Repair
Description: composed of biomimetic regeneration scaffold self-assembling peptides (P11-4) used for remineralization
Study NCT02913885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluoride varnish
Description: fluoride inhibit the progression of white spot lesion
Study NCT02913885 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluoride varnish
Description: fluoride inhibit the progression of white spot lesion
Study NCT03123549 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Simplify Disc
Description: Simplify Disc at two levels of the cervical spine
Study NCT02293200 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard BLS
Description: basic life support without any feedback device
Study NCT02293200 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TrueCPR
Description: CPR with feedback device
Study NCT04787276 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: E.coli Nissle 1917
Description: Probiotic contains biomass of E.coli Nissle 1917, 2,5-25·109 colony forming units - CFU/g
Study NCT04787276 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactulose
Description: will receive 30-60 ml of lactulose in 2 or 3 divided doses so that patient passed 2-3 semisoft stools per day, 1 months of treatment
Study NCT04787276 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifaximin
Description: rifaximin, oral, 500 mg BID, 1 months of treatment
Study NCT01751269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPX7009
Description: Ten (10) cohorts of 8 subjects (6 active and 2 placebo) are planned for evaluation.
Study NCT01751269 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ten (10) cohorts of 8 subjects (6 active and 2 placebo) are planned for evaluation.
Study NCT00243789 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pentoxifylline
Description: Participants will be randomized to receive either pentoxifylline or placebo in addition to their stable steroid therapy. Active drug and placebo preparations will be supplied as gel capsules of identical size, appearance and taste. Active drug capsules will contain one 400 mg time-release pentoxifylline tablet and inert filler. Placebo capsules will contain inert filler.~Based on weight at screening, \<30 mg will receive 1 400 capsule/day; 30-49 kg will receive two 400 capsules/day; 50 kg or greater will receive three 400 mg capsules/day.
Study NCT03071627 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: New items with spin
Description: Interpretation of news items with spin
Study NCT03071627 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: New items without spin
Description: Interpretation of news items without spin
Study NCT03077802 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified Seldinger technique, Experienced group
Description: This is a technique for central venous catheterization. We will use needle that is covered with guiding sheath. After desired vessel puncture, guiding sheath is instantly slid over the needle into the vessel. The needle is withdrawn, guidewire is advanced through the guiding sheath, central catheter is placed into the vessel. The procedure will be performed by experienced practitioners who are board-certified anesthesiologist staffs and have experience of more than 50 central venous catheterizations in both techniques.
Study NCT03602742 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: EZYPRO®
Description: Wear two devices including 24-hour Holter and 14-day continuous EZYPRO® to evaluate the performance
Study NCT04272749 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assess opinons on the milk beverages
Description: Questionnaires and consumption behaviors of dairy and non-dairy milks, including whole, 2% fat, 1% fat, skim, unsweetened almond, sweetened almond, unsweetened coconut, sweetened coconut, unsweetened soy, sweetened soy, unsweetened rice, and sweetened rice.....
Study NCT02090166 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood test
Description: a blood test will be taken from each patient
Study NCT02943590 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A pill taken once a day
Study NCT03677661 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional approach
Description: The intervention will consist of light cognitive and physical activity with no symptoms exacerbation followed by graded exertion. Participant will be evaluated by a neuropsychologist. The neuropsychological intervention will consist of advice relative to cognitive rest in line with the clinical evaluation results followed by an individualized step-by-step graded exposition to cognitive stimulus according to symptoms evolution. A kinesiologist will also evaluate the symptoms response to cardio-vascular exertion. According to the result of this clinical evaluation, a graded physical exercise program will be given to the participants. 8 in-clinic cardio-vascular exercise sessions in a 6-week period supervised by the kinesiologist (30 to 45 minutes each session) will be provided.
Study NCT03677661 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized rehabilitation program
Description: The same advice and exercise program than the active comparator group will be provided. However, 2 physiotherapists will provide 8 treatment session ( 30 to 45 minutes). One physiotherapist will initially evaluate the physical dysfunctions associated to mTBI with a standardized evaluation to build the treatment plan. He will provide cervical manual therapy and therapeutic exercises based on the best current clinical approach and according to the impairment specifically found initially. A vestibular physiotherapist will provide treatment of canalith repositioning manoeuvre, vestibular adaptation, ocular motor exercises, balance and/or habituation exercises. This treatment will be adapted to the individual patient. No more than 8 sessions will be delivered.
Study NCT03115021 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tPCS
Description: A current intensity of 2na and a stimulation frequency range of 6-10 Hz will be used with a peri-auricular ear-clip electrode montage for 20 minutes.
Study NCT03115021 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tDCS
Description: A current intensity of 2mA will be used for 20minutes. The electrodes that will be used will be standard sponge electrodes. The anode will be place over the left prefrontal cortex and the cathode over the right supraorbitofrontal area.
Study NCT03115021 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham tPCS
Description: Sham tPCS will consist of applying the same parameters as for active but the corresponding device will be turned off after 30 seconds as to simulate the initial sensation of the active current. A current of 2mA will still be used (but turned off after 30 sec). The electrodes that will be used will be the same as for the active tPCS condition and the electrodes placement as well.
Study NCT02061397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus Oral Product
Description: Eligible patients on everolimus will be assigned to receive 20 mg of simvastatin once daily for a period of two months. If tolerated, the dosage of simvastatin will be advanced to 40 mg once daily in months 3 and 4.
Study NCT03077802 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Seldinger technique, Experienced group
Description: This is a technique for central venous catheterization. The desired vessel is punctured with a sharp hollow needle, syringe is detached and guidewire is advanced through the lumen of the needle, and then the needle is withdrawn. Central catheter is then passed over the guidewire into the vessel. The procedure will be performed by experienced practitioners who are board-certified anesthesiologist staffs and have experience of more than 50 central venous catheterizations in both techniques.
Study NCT05066646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT103A
Description: CT103A consists of autologous T lymphocytes transduced with anti-BCMA CAR lentiviral vector that containing a unique CAR structure with a fully human single-chain variable fragment (scFv).
Study NCT03556098 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glucose-dependent insulinotropic peptide
Description: Infusion of GIP
Study NCT02943590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: A pill taken once a day
Study NCT01827865 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etodolac Extended Release Tablets USP 600mg
Description: Etodolac Extended Release Tablets USP 600mg once a day
Study NCT03556098 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucose-Dependent Insulin-Releasing Hormone[3-30]
Description: Infusion of GIP antagonist GIP\[3-30\]
Study NCT03556098 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution
Description: Infusion of Saline
Study NCT04069377 — intervention group
Intervention type: DEVICE
Intervention: LUCAS™ 2 Chest Compression System
Description: LUCAS is a portable device designed to rule out the problems encountered during manual chest compression, capable of performing standard and continuous chest compressions at a depth of 4-5 cm and at least 100 times per minute.
Study NCT04069377 — intervention group
Intervention type: OTHER
Intervention: Manuel chest compressions by human efforts
Description: In this way chest compressions will be handled by humans themselves.
Study NCT01994863 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coloplast Test product
Description: Coloplast test product is a newly developed 1-piece ostomy appliance
Study NCT01994863 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard Care
Description: Standard care consists of three already marketed 1-piece ostomy products~Coloplast SenSura Hollister Moderma/Moderma Flex B.Braun Flexima/Softima
Study NCT00203112 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glatiramer acetate with minocycline
Description: Subcutaneous injection glatiramer acetate 20mg, with oral minocycline 100mg
Study NCT01827865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etodolac Extended Release Tablets USP 600mg
Description: Etodolac Extended Release Tablets USP 600mg once a day
Study NCT01827865 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etodolac Extended Release Tablets 600mg
Description: Etodolac Extended Release Tablets 600mg once a day
Study NCT00203112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glatiramer acetate with placebo
Description: Subcutaneous injection glatiramer acetate 20mg, with oral placebo
Study NCT01827865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etodolac Extended Release Tablets 600mg
Description: Etodolac Extended Release Tablets 600mg once a day
Study NCT03103516 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: early epidural decompression group
Description: The patients will be assigned to early (within 24 hours after spinal cord injury) epidural decompression group (n=100) according to the patient's condition and operation time.
Study NCT01039610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK945237
Description: Dose detailed in Arm description
Study NCT03103516 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: delayed epidural decompression group
Description: The patients will be assigned to delayed (exceed 24 hours after spinal cord injury) epidural decompression group (n=100) according to the patient's condition and operation time.
Study NCT03972319 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 2 capsules of Concentrated omega-3 triglycerides- fish 1000mg (600mg Eicosapentaenoic acid (EPA), 1400mg Docosahexaenoic acid (DHA)) per day
Description: 4 weeks course of Omega-3 (2 capsules of Blackmores Omega Daily Concentrated Fish Oil per day
Study NCT03023254 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Hydrotherapy
Description: 3-week Avène hydrotherapy
Study NCT00733135 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: SilverHawk™ LS-C, TurboHawk™ LS-C, TurboHawk™ LX-C plaque excision systems and SpiderFX™ embolic protection device
Description: Catheter-based excision of moderate to severely calcified plaque located in the SFA and/or popliteal artery.
Study NCT03084913 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Plant- based, olive oil diet
Description: used as part of daily diet, followed for 8 weeks
Study NCT03084913 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plant- based, olive oil diet
Description: used as part of daily diet, followed for 8 weeks
Study NCT03084913 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Prostate Cancer Foundation diet
Description: followed for 8 weeks
Study NCT03084913 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prostate Cancer Foundation diet
Description: followed for 8 weeks